<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436370</url>
  </required_header>
  <id_info>
    <org_study_id>10-0076</org_study_id>
    <nct_id>NCT01436370</nct_id>
  </id_info>
  <brief_title>TIV and High Dose TIV in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving
      TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched
      control subjects . This study will investigate the immunogenicity, safety, and reactogenicity
      of two different doses of inactivated trivalent influenza virus vaccine (Sanofi Pasteur
      Fluzone [15 mcg x 3 strains] and Sanofi Pasteur Fluzone High Dose [60 mcg x 3 strains])
      administered intramuscularly in individuals with rheumatoid arthritis receiving
      anti-TNF-alpha (TNFi) therapy and healthy age- and gender- matched controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis
      receiving TNF-alpha inhibitor therapy, aged 18 years to 64 years of age. This study is
      designed to investigate the immunogenicity, safety, and reactogenicity of two different doses
      of inactivated trivalent influenza virus vaccine given at two dose levels (15 mcg and 60 mcg)
      administered IM in individuals with rheumatoid arthritis receiving anti-TNF-alpha therapy or
      age and gender matched control subjects. The study is conducted over two seasons, 2011-2012
      and 2012-2013. Subjects enrolling between October 2011 and February 2012 will receive the
      2011-2012 vaccine, while those enrolling after July 2012 will receive the 2012-2013 vaccine.
      Immunogenicity testing will determine the proportion of subjects in each group with titer a
      4-fold rise in HAI titers (defined as either a pre-vaccination HAI titer &lt;1:10 and a
      post-vaccination HAI titer &gt;/=1:40 or a pre-vaccination HAI titer &gt;/=1:10 and a minimum
      four-fold rise in post-vaccination HAI titer) against each of the specific influenza strains
      included in vaccine the subject received at day 21 following vaccination. The proportion of
      subjects in each group achieving a serum HAI titer of &gt;/= 1:40 or a 4-fold rise in HAI titer
      or greater in HAI titer against each strain in the vaccine compared to the controls subjects.
      Safety testing will assess the occurrence of vaccine-associated Serious adverse events (SAEs)
      throughout the course of the study, and the occurrence of solicited local and systemic
      adverse events (AEs) within 8 days post vaccination. Solicited AEs (including rheumatoid
      arthritis clinical status) will be assessed during the course of the study. Subjects will
      have four face to face visits and one telephone contact. Day 0 will include the consent
      process, a medical history and physical exam for the RA subjects to assess the activity of
      their RA at the time of enrollment, vital signs, phlebotomy for prevaccine serology. Subjects
      will be randomized to receive IM seasonal TIV or High-Dose TIV at this visit and will receive
      the assigned vaccine. They will be observed for 20 minutes and will be taught to fill out a 7
      day memory aid that will assess daily temperature, local and systemic reactogenicity. A
      telephone call will be made to assess reactogenicity and to review the memory aid on day 3.
      Subjects will return on day 7 for review of the memory aid, AEs/SAEs, vital signs and
      phlebotomy for serology. A physical exam will be performed if indicated. They will return on
      day 21 and at 6 months for review of AEs/SAEs, vital signs and phlebotomy for serology. A
      physical exam will be performed if indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</measure>
    <time_frame>Day 0 prior to and Day 21 following immunization</time_frame>
    <description>Blood was collected from RA participants prior to vaccination and at the 21 day follow up visit for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</measure>
    <time_frame>Day 0 prior to and Day 21 following immunization</time_frame>
    <description>Blood was collected from RA participants prior to vaccination and at the 21 day follow up visit for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Vaccine-related Serious Adverse Events (SAEs) Throughout the Course of the Study.</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof; resulted in a congenital anomaly/birth defect; or may have jeopardized the participant or required intervention to prevent one of these outcomes. Association to vaccination was determined by a study clinician licensed to make medical diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) for Each of the Specific Influenza Strains Included in Vaccine Received by Participants in the 2011-2012 Season</measure>
    <time_frame>Days 0, 7, 21 and 180</time_frame>
    <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 7, 21 and 180 days following vaccination. The HAI assay was conducted with the three antigens in the 2011-2012 seasonal inactivated TIV. Within each 2011-2012 study arm, geometric mean titers and 95% confidence intervals were calculated for each antigen separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) for Each of the Specific Influenza Strains Included in Vaccine Received by Participants in the 2012-2013 Season</measure>
    <time_frame>Days 0, 7, 21 and 180</time_frame>
    <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 7, 21 and 180 days following vaccination. The HAI assay was conducted with the three antigens in the 2012-2013 seasonal inactivated TIV. Within each 2012-2013 study arm, geometric mean titers and 95% confidence intervals were calculated for each antigen separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Systemic Symptoms Based on a Functional Grading Scale</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, chills, arthralgia, shivering, and asthenia for 8 days after vaccination (Day 0-7) based on their interference with daily activities, with a severity grade of mild meaning no interference, moderate as some interference and severe as significant interference/prevented daily activity. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Fever</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>Participants were provided with a thermometer and a memory aid on which to record daily oral temperatures for 8 days after vaccination (Day 0-7). The protocol defined fever as oral temperature of 38.0 degrees Celsius or higher. Participants are counted as experiencing fever if they reported oral temperatures of 38.0 degrees Celsius or higher on any of the 8 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Local Injection Site Reactions Based on a Functional Grading Scale</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of local injection site reactions of pain, tenderness, redness, and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities, with a severity grade of mild meaning no interference, moderate as some interference and severe as significant interference/prevented daily activity. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Quantitative Local Injection Site Reactions</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Days 7 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</measure>
    <time_frame>Day 0 prior to and Days 7 and 180 following immunization</time_frame>
    <description>Blood was collected from RA participants prior to vaccination and at the Days 7 and 180 follow up visits for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Days 7 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</measure>
    <time_frame>Day 0 prior to and Days 7 and 180 following immunization</time_frame>
    <description>Blood was collected from RA participants prior to vaccination and at the Days 7 and 180 follow up visits for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RA Participants With a Worsening Rheumatoid Arthritis Status During the Course of the Study, Based on the RAPID3 Score From the NP2 Questionnaire</measure>
    <time_frame>Day 0 to Days 7, 21 and 180</time_frame>
    <description>The RAPID 3 score is an index of the three patient-reported measures from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ) R808 and serves as an assessment of patient status for those with rheumatoid arthritis. The score consists of the cumulative total of the Function (FN), Pain (PN), and Patient Global (PTGL) values. The severity of the RAPID 3 score is categorized as: &gt;12=High Severity; 6.1-12=Moderate Severity; 3.1-6=Low Severity; and ≤3=Remission. The NP2 questionnaire was completed by RA participants at all clinic visits. Scores at Days 7, 21 and 180 were compared to Day 0 to determine worsening, defined as moving from the baseline category to a more severe category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in the 2011-2012 Season Who Achieved Seroconversion at Days 7, 21 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</measure>
    <time_frame>Day 0 prior to and Days 7, 21 and 180 following immunization</time_frame>
    <description>Blood was collected from all participants prior to vaccination and at the Days 7, 21 and 180 follow up visits for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in the 2012-2013 Season Who Achieved Seroconversion at Days 7, 21 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</measure>
    <time_frame>Day 0 prior to and Days 7, 21 and 180 following immunization</time_frame>
    <description>Blood was collected from all participants prior to vaccination and at the Days 7, 21 and 180 follow up visits for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1 Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent inactivated influenza vaccine</intervention_name>
    <description>Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 2 Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent inactivated influenza vaccine</intervention_name>
    <description>Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 1 Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for RA Subjects

          -  Male or non-pregnant female between the ages of 18 and 64 years, inclusive, who has
             stable RA and has received TNFi therapy during the previous 3 months.

          -  Female subjects: for the 30 days prior to enrollment through 30 days following receipt
             of TIV or HTIV vaccine must fulfill one of the following: (i) she is not able to bear
             children because she has been surgically sterilized (tubal ligation or hysterectomy)
             for at least one year or is at least 1 year post-menopausal or (ii) she agrees to
             practice effective methods of contraception including, but not limited to, abstinence,
             barrier methods (such as a condom or diaphragm) used with a spermicide, birth control
             pills, patches or hormonal shots or hormonal implants, NuvaRing and IUDs (intrauterine
             devices). Adherence to contraceptive method will be captured on the appropriate case
             report form (CRF).

          -  In good health, as determined by vital signs (see toxicity table in section 9.2.1.1),
             medical history to ensure any existing medical diagnoses or conditions are stable and
             not considered clinically significant, and physical examination.

          -  Intend to be available through 6 months following receipt of vaccine.

          -  Able to understand and comply with planned study procedures.

          -  Provide written informed consent prior to initiation of any study procedures.

        Inclusion Criteria for Healthy Subjects

          -  Male or non-pregnant female between the ages of 18 and 64 years, inclusive.

          -  Female subjects: for the 30 days prior to enrollment through 30 days following receipt
             of TIV or HTIV vaccine must fulfill one of the following: (i) she is not able to bear
             children because she has been surgically sterilized (tubal ligation or hysterectomy)
             for at least one year or is at least 1 year post-menopausal or (ii) she agrees to
             practice effective methods of contraception including, but not limited to, abstinence,
             barrier methods (such as a condom or diaphragm) used with a spermicide, birth control
             pills, patches or hormonal shots or hormonal implants, NuvaRing and IUDs (intrauterine
             devices). Adherence to contraceptive method will be captured on the appropriate case
             report form (CRF).

          -  In good health, as determined by vital signs (see toxicity table in section 9.2.1.1),
             medical history to ensure any existing medical diagnoses or conditions are stable and
             not considered clinically significant, and physical examination.

          -  Intend to be available through 6 months following receipt of vaccine.

          -  Able to understand and comply with planned study procedures.

          -  Provide written informed consent prior to initiation of any study procedures.

        Exclusion Criteria:

        Exclusion Criteria for all Subjects

          -  For subjects enrolled after July 2012: Enrolled in this study during the 2011-2012 flu
             season.

          -  Has received the seasonal influenza vaccine for the current season. For subjects
             enrolling between October 2011 and February 2012, this is the 2011-2012 seasonal
             influenza vaccine. For subjects enrolling after July 2012, this is the 2012-2013
             seasonal influenza vaccine.

          -  Has a known allergy to eggs, egg proteins or other components in the vaccines (i.e.
             formaldehyde, gelatin sodium phosphate, sodium chloride, octylphenol ethoxylate).

          -  Has a known or suspected latex allergy or sensitivity.

          -  Has a positive urine or serum pregnancy test within 24 hours prior to vaccination (if
             female of childbearing potential as defined in Inclusion criterion 2), or women who
             are breastfeeding.

          -  Has a history of severe reactions following immunization with contemporary influenza
             virus vaccines.

          -  Has an active neoplastic disease or a history of any hematologic malignancy (cancers
             of blood or bone marrow) or current bleeding or blood clotting disorder.

          -  For &quot;healthy volunteer&quot; (without RA) subjects: Long term (at least 14 days of
             prednisone 2 mg/kg or equivalent other glucocorticoid) use of oral, parenteral or
             high-dose inhaled steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent)
             within the preceding 6 months. (Nasal and topical steroids are allowed.)

          -  Has a diagnosis of a current and uncontrolled major psychiatric disorder.

          -  Has been hospitalized in the past 10 years for psychiatric illness, suicide attempt,
             or confinement for danger to self or others.

          -  Is receiving listed psychiatric drugs as below*. Subjects who are receiving a single
             antidepressant drug and are stable for at least 3 months prior to enrollment, without
             decompensating are allowed enrollment into the study.

             * aripiprazole, clozapine, ziprasidone, haloperidol, molindone, loxapine,
             thioridazine, thiothixene, pimozide, fluphenazine, risperidone, mesoridazine,
             quetiapine, trifluoperazine, chlorprothixene, chlorpromazine, perphenazine,
             trifluopromazine, olanzapine, carbamazepine, divalproex sodium, lithium carbonate,
             lithium citrate, lamotrigine, prochlorperazine, paliperidone or iloperidone.

          -  Has a history of receiving immunoglobulin or other blood product within the 3 months
             prior to vaccination in this study.

          -  Has received an experimental/investigational agent (vaccine, drug, biologic, device,
             blood product, or medication) within 28 days prior to vaccination in this study, or
             expects to receive an experimental/investigational agent within the study time period
             (180 days after vaccination in this study).

          -  Is participating or plans to participate in another clinical trial with a licensed
             product during the 6-month study period.

          -  Has received any other licensed vaccines within 14 days (for inactivated vaccines) or
             21 days (for live vaccines) prior to vaccination in this study, or expects to receive
             a licensed vaccine during the 21 days after vaccination in this study.

          -  Has received antiviral agent against influenza A and/or B within 48 hours prior to
             vaccination in this study. Antiviral agents should not be administered until 2 weeks
             after vaccination in this study unless medically necessary.

          -  Has an acute or chronic medical condition other than RA that, in the opinion of the
             investigator, would interfere with the evaluation of responses (this includes, but is
             not limited to: known chronic liver, lung or heart disease, chronic anemia, (non-RA
             subjects only), metabolic disorders such as diabetes (resolved gestational diabetes is
             acceptable), significant renal disease, transplant recipients, system lupus
             erythematosus, psoriatic arthritis or gout).

          -  Has a moderate to severe acute illness and/or an oral temperature greater than or
             equal to 100.4 degrees Fahrenheit, within 72 hours prior to vaccination. (This may
             result in a temporary delay of vaccination).

          -  Immunosuppression as a result of an underlying illness or treatment other than RA
             therapy, or use of anti-cancer chemotherapy or radiation therapy within the preceding
             36 months.

          -  Known infection with HIV, Hepatitis B or Hepatitis C infection or autoimmune
             hepatitis.

          -  Has a history of alcohol or drug abuse in the last 5 years.

          -  Has a history of Guillain-Barré Syndrome.

          -  Has any condition that would, in the opinion of the site investigator, place the
             subject at an unacceptable risk or render the subject unable to meet the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa - Vaccine Research &amp; Education Unit</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>April 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2014</results_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza, rheumatoid arthritis, TNF-alpha-inhibitor, Fluzone®, Fluzone® High Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults with rheumatoid arthritis (RA) receiving tumor necrosis factor (TNF)-alpha-inhibitor therapy and healthy controls were recruited from existing volunteer populations and the community around the clinical site. Participants were enrolled between 20OCT2011 - 3JAN2012 (2011-2012 vaccine); and 12SEP2012 -14JAN2013 (2012-2013 vaccine).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
          <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="P3">
          <title>RA Participants, 2011-2012 Fluzone High Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="P4">
          <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
          <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="P5">
          <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="P6">
          <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
          <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="P7">
          <title>RA Participants, 2012-2013 Fluzone High Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="P8">
          <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
          <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population includes all participants who were enrolled and vaccinated.</population>
      <group_list>
        <group group_id="B1">
          <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
          <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="B3">
          <title>RA Participants, 2011-2012 Fluzone High Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="B4">
          <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
          <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="B5">
          <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="B6">
          <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
          <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="B7">
          <title>RA Participants, 2012-2013 Fluzone High Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="B8">
          <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
          <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="19"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="16"/>
            <count group_id="B8" value="16"/>
            <count group_id="B9" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="9.3"/>
                    <measurement group_id="B2" value="46.4" spread="9.4"/>
                    <measurement group_id="B3" value="47.6" spread="9.5"/>
                    <measurement group_id="B4" value="48.3" spread="10.1"/>
                    <measurement group_id="B5" value="49.8" spread="11.0"/>
                    <measurement group_id="B6" value="50.1" spread="10.8"/>
                    <measurement group_id="B7" value="52.8" spread="9.5"/>
                    <measurement group_id="B8" value="52.1" spread="9.4"/>
                    <measurement group_id="B9" value="49.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
        <description>Blood was collected from RA participants prior to vaccination and at the 21 day follow up visit for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
        <time_frame>Day 0 prior to and Day 21 following immunization</time_frame>
        <population>The analysis population includes all RA participants enrolled and vaccinated with the 2011-2012 vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
          <description>Blood was collected from RA participants prior to vaccination and at the 21 day follow up visit for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
          <population>The analysis population includes all RA participants enrolled and vaccinated with the 2011-2012 vaccines.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Brisbane/60/2008 strain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Perth/16/2009 (A/H3N2) strain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Vaccine-related Serious Adverse Events (SAEs) Throughout the Course of the Study.</title>
        <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof; resulted in a congenital anomaly/birth defect; or may have jeopardized the participant or required intervention to prevent one of these outcomes. Association to vaccination was determined by a study clinician licensed to make medical diagnosis.</description>
        <time_frame>Day 0 to Day 180</time_frame>
        <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O5">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O6">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O7">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O8">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Vaccine-related Serious Adverse Events (SAEs) Throughout the Course of the Study.</title>
          <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof; resulted in a congenital anomaly/birth defect; or may have jeopardized the participant or required intervention to prevent one of these outcomes. Association to vaccination was determined by a study clinician licensed to make medical diagnosis.</description>
          <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) for Each of the Specific Influenza Strains Included in Vaccine Received by Participants in the 2011-2012 Season</title>
        <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 7, 21 and 180 days following vaccination. The HAI assay was conducted with the three antigens in the 2011-2012 seasonal inactivated TIV. Within each 2011-2012 study arm, geometric mean titers and 95% confidence intervals were calculated for each antigen separately.</description>
        <time_frame>Days 0, 7, 21 and 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) for Each of the Specific Influenza Strains Included in Vaccine Received by Participants in the 2011-2012 Season</title>
          <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 7, 21 and 180 days following vaccination. The HAI assay was conducted with the three antigens in the 2011-2012 seasonal inactivated TIV. Within each 2011-2012 study arm, geometric mean titers and 95% confidence intervals were calculated for each antigen separately.</description>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="7.7" upper_limit="65.5"/>
                    <measurement group_id="O2" value="20.0" lower_limit="4.3" upper_limit="92.0"/>
                    <measurement group_id="O3" value="24.6" lower_limit="11.3" upper_limit="53.6"/>
                    <measurement group_id="O4" value="23.0" lower_limit="11.1" upper_limit="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="15.0" upper_limit="67.3"/>
                    <measurement group_id="O2" value="56.6" lower_limit="23.2" upper_limit="137.9"/>
                    <measurement group_id="O3" value="74.6" lower_limit="32.7" upper_limit="170.3"/>
                    <measurement group_id="O4" value="80.0" lower_limit="32.4" upper_limit="197.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="14.3" upper_limit="111.9"/>
                    <measurement group_id="O2" value="56.6" lower_limit="20.8" upper_limit="154.2"/>
                    <measurement group_id="O3" value="121.3" lower_limit="50.3" upper_limit="292.6"/>
                    <measurement group_id="O4" value="130.0" lower_limit="57.7" upper_limit="292.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" lower_limit="9.4" upper_limit="85.2"/>
                    <measurement group_id="O2" value="35.6" lower_limit="12.2" upper_limit="104.0"/>
                    <measurement group_id="O3" value="56.6" lower_limit="24.2" upper_limit="132.5"/>
                    <measurement group_id="O4" value="56.6" lower_limit="26.8" upper_limit="119.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" lower_limit="11.7" upper_limit="273.8"/>
                    <measurement group_id="O2" value="22.4" lower_limit="6.4" upper_limit="78.6"/>
                    <measurement group_id="O3" value="37.3" lower_limit="11.7" upper_limit="118.6"/>
                    <measurement group_id="O4" value="41.4" lower_limit="12.4" upper_limit="138.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="23.6" upper_limit="341.1"/>
                    <measurement group_id="O2" value="89.8" lower_limit="38.4" upper_limit="210.2"/>
                    <measurement group_id="O3" value="197.0" lower_limit="75.0" upper_limit="517.1"/>
                    <measurement group_id="O4" value="139.3" lower_limit="56.7" upper_limit="342.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="23.6" upper_limit="341.1"/>
                    <measurement group_id="O2" value="71.3" lower_limit="24.4" upper_limit="207.9"/>
                    <measurement group_id="O3" value="211.1" lower_limit="93.3" upper_limit="477.6"/>
                    <measurement group_id="O4" value="171.5" lower_limit="83.6" upper_limit="351.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="15.1" upper_limit="337.3"/>
                    <measurement group_id="O2" value="35.6" lower_limit="15.2" upper_limit="83.4"/>
                    <measurement group_id="O3" value="65.0" lower_limit="24.8" upper_limit="170.6"/>
                    <measurement group_id="O4" value="74.6" lower_limit="28.9" upper_limit="192.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="3.2" upper_limit="30.9"/>
                    <measurement group_id="O2" value="20.0" lower_limit="2.8" upper_limit="140.8"/>
                    <measurement group_id="O3" value="32.5" lower_limit="13.5" upper_limit="78.0"/>
                    <measurement group_id="O4" value="42.1" lower_limit="17.6" upper_limit="101.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" lower_limit="14.0" upper_limit="144.0"/>
                    <measurement group_id="O2" value="142.5" lower_limit="37.5" upper_limit="541.5"/>
                    <measurement group_id="O3" value="160.0" lower_limit="68.9" upper_limit="371.7"/>
                    <measurement group_id="O4" value="242.5" lower_limit="94.7" upper_limit="621.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" lower_limit="23.8" upper_limit="106.8"/>
                    <measurement group_id="O2" value="285.1" lower_limit="41.8" upper_limit="1944.5"/>
                    <measurement group_id="O3" value="288.4" lower_limit="88.6" upper_limit="939.2"/>
                    <measurement group_id="O4" value="242.5" lower_limit="129.5" upper_limit="454.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="5.3" upper_limit="47.5"/>
                    <measurement group_id="O2" value="142.5" lower_limit="32.3" upper_limit="629.2"/>
                    <measurement group_id="O3" value="91.9" lower_limit="30.9" upper_limit="273.7"/>
                    <measurement group_id="O4" value="85.7" lower_limit="45.3" upper_limit="162.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) for Each of the Specific Influenza Strains Included in Vaccine Received by Participants in the 2012-2013 Season</title>
        <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 7, 21 and 180 days following vaccination. The HAI assay was conducted with the three antigens in the 2012-2013 seasonal inactivated TIV. Within each 2012-2013 study arm, geometric mean titers and 95% confidence intervals were calculated for each antigen separately.</description>
        <time_frame>Days 0, 7, 21 and 180</time_frame>
        <population>The analysis population includes all participants enrolled and vaccinated with the 2012-2013 vaccines who had blood collected at the visit. One RA Participant, Standard Dose and one Healthy Control, High Dose recipient are not included at Day 180 because the participant was out of window and lost to follow-up, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) for Each of the Specific Influenza Strains Included in Vaccine Received by Participants in the 2012-2013 Season</title>
          <description>Blood was collected for HAI assay at Day 0 prior to vaccination and again at 7, 21 and 180 days following vaccination. The HAI assay was conducted with the three antigens in the 2012-2013 seasonal inactivated TIV. Within each 2012-2013 study arm, geometric mean titers and 95% confidence intervals were calculated for each antigen separately.</description>
          <population>The analysis population includes all participants enrolled and vaccinated with the 2012-2013 vaccines who had blood collected at the visit. One RA Participant, Standard Dose and one Healthy Control, High Dose recipient are not included at Day 180 because the participant was out of window and lost to follow-up, respectively.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Wisconsin/1/2010 - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="6.3" upper_limit="15.8"/>
                    <measurement group_id="O2" value="9.6" lower_limit="6.4" upper_limit="14.5"/>
                    <measurement group_id="O3" value="9.8" lower_limit="6.7" upper_limit="14.4"/>
                    <measurement group_id="O4" value="7.1" lower_limit="5.3" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Wisconsin/1/2010 - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="12.4" upper_limit="38.7"/>
                    <measurement group_id="O2" value="11.8" lower_limit="7.9" upper_limit="17.6"/>
                    <measurement group_id="O3" value="35.1" lower_limit="21.1" upper_limit="58.4"/>
                    <measurement group_id="O4" value="19.6" lower_limit="12.3" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Wisconsin/1/2010 - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="16.1" upper_limit="44.6"/>
                    <measurement group_id="O2" value="14.4" lower_limit="9.6" upper_limit="21.6"/>
                    <measurement group_id="O3" value="51.9" lower_limit="32.3" upper_limit="83.4"/>
                    <measurement group_id="O4" value="20.0" lower_limit="13.7" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Wisconsin/1/2010 - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="8.6" upper_limit="27.1"/>
                    <measurement group_id="O2" value="10.8" lower_limit="7.4" upper_limit="15.7"/>
                    <measurement group_id="O3" value="16.1" lower_limit="10.1" upper_limit="25.7"/>
                    <measurement group_id="O4" value="9.1" lower_limit="6.2" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="19.7" upper_limit="75.4"/>
                    <measurement group_id="O2" value="38.6" lower_limit="21.7" upper_limit="68.6"/>
                    <measurement group_id="O3" value="39.1" lower_limit="16.6" upper_limit="92.5"/>
                    <measurement group_id="O4" value="45.6" lower_limit="21.2" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1" lower_limit="62.7" upper_limit="189.8"/>
                    <measurement group_id="O2" value="97.8" lower_limit="52.7" upper_limit="181.5"/>
                    <measurement group_id="O3" value="167.1" lower_limit="75.7" upper_limit="368.8"/>
                    <measurement group_id="O4" value="226.3" lower_limit="125.7" upper_limit="407.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.4" lower_limit="81.0" upper_limit="253.8"/>
                    <measurement group_id="O2" value="113.1" lower_limit="60.9" upper_limit="210.3"/>
                    <measurement group_id="O3" value="257.7" lower_limit="136.9" upper_limit="484.9"/>
                    <measurement group_id="O4" value="252.2" lower_limit="135.6" upper_limit="469.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="39.7" upper_limit="155.0"/>
                    <measurement group_id="O2" value="59.8" lower_limit="33.2" upper_limit="107.5"/>
                    <measurement group_id="O3" value="115.6" lower_limit="58.8" upper_limit="227.3"/>
                    <measurement group_id="O4" value="100.8" lower_limit="56.5" upper_limit="179.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="19.1" upper_limit="53.1"/>
                    <measurement group_id="O2" value="92.6" lower_limit="50.6" upper_limit="169.2"/>
                    <measurement group_id="O3" value="35.1" lower_limit="19.4" upper_limit="63.4"/>
                    <measurement group_id="O4" value="49.7" lower_limit="20.6" upper_limit="119.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="52.2" upper_limit="158.3"/>
                    <measurement group_id="O2" value="148.7" lower_limit="87.3" upper_limit="253.4"/>
                    <measurement group_id="O3" value="207.5" lower_limit="81.6" upper_limit="527.6"/>
                    <measurement group_id="O4" value="203.0" lower_limit="93.9" upper_limit="439.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.6" lower_limit="75.7" upper_limit="192.0"/>
                    <measurement group_id="O2" value="160.0" lower_limit="88.8" upper_limit="288.4"/>
                    <measurement group_id="O3" value="442.9" lower_limit="232.4" upper_limit="844.0"/>
                    <measurement group_id="O4" value="226.3" lower_limit="109.8" upper_limit="466.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="28.3" upper_limit="86.4"/>
                    <measurement group_id="O2" value="117.3" lower_limit="61.2" upper_limit="225.1"/>
                    <measurement group_id="O3" value="123.4" lower_limit="55.8" upper_limit="272.8"/>
                    <measurement group_id="O4" value="96.2" lower_limit="37.3" upper_limit="248.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Systemic Symptoms Based on a Functional Grading Scale</title>
        <description>Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, chills, arthralgia, shivering, and asthenia for 8 days after vaccination (Day 0-7) based on their interference with daily activities, with a severity grade of mild meaning no interference, moderate as some interference and severe as significant interference/prevented daily activity. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
        <time_frame>Day 0 to Day 7</time_frame>
        <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O5">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O6">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O7">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O8">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Systemic Symptoms Based on a Functional Grading Scale</title>
          <description>Participants maintained a memory aid to record daily the occurrence of systemic symptoms of feverishness, malaise, myalgia, headache, nausea, chills, arthralgia, shivering, and asthenia for 8 days after vaccination (Day 0-7) based on their interference with daily activities, with a severity grade of mild meaning no interference, moderate as some interference and severe as significant interference/prevented daily activity. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
          <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Fever</title>
        <description>Participants were provided with a thermometer and a memory aid on which to record daily oral temperatures for 8 days after vaccination (Day 0-7). The protocol defined fever as oral temperature of 38.0 degrees Celsius or higher. Participants are counted as experiencing fever if they reported oral temperatures of 38.0 degrees Celsius or higher on any of the 8 days.</description>
        <time_frame>Day 0 to Day 7</time_frame>
        <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O5">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O6">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O7">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O8">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Fever</title>
          <description>Participants were provided with a thermometer and a memory aid on which to record daily oral temperatures for 8 days after vaccination (Day 0-7). The protocol defined fever as oral temperature of 38.0 degrees Celsius or higher. Participants are counted as experiencing fever if they reported oral temperatures of 38.0 degrees Celsius or higher on any of the 8 days.</description>
          <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Local Injection Site Reactions Based on a Functional Grading Scale</title>
        <description>Participants maintained a memory aid to record daily the occurrence of local injection site reactions of pain, tenderness, redness, and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities, with a severity grade of mild meaning no interference, moderate as some interference and severe as significant interference/prevented daily activity. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
        <time_frame>Day 0 to Day 7</time_frame>
        <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O5">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O6">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O7">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O8">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local Injection Site Reactions Based on a Functional Grading Scale</title>
          <description>Participants maintained a memory aid to record daily the occurrence of local injection site reactions of pain, tenderness, redness, and swelling for 8 days after vaccination (Day 0-7) based on their interference with daily activities, with a severity grade of mild meaning no interference, moderate as some interference and severe as significant interference/prevented daily activity. Participants are counted if they reported experiencing the symptom at any severity on any of the 8 days.</description>
          <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Quantitative Local Injection Site Reactions</title>
        <description>Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.</description>
        <time_frame>Day 0 to Day 7</time_frame>
        <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O5">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O6">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O7">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O8">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Quantitative Local Injection Site Reactions</title>
          <description>Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.</description>
          <population>The analysis population includes all participants enrolled and vaccinated in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
        <description>Blood was collected from RA participants prior to vaccination and at the 21 day follow up visit for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
        <time_frame>Day 0 prior to and Day 21 following immunization</time_frame>
        <population>The analysis population includes all RA participants enrolled and vaccinated with the 2012-2013 vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
          <description>Blood was collected from RA participants prior to vaccination and at the 21 day follow up visit for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
          <population>The analysis population includes all RA participants enrolled and vaccinated with the 2012-2013 vaccines.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Wisconsin/1/2010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Wisconsin/1/2010 strain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Victoria/361/2011 (A/H3N2) strain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Days 7 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
        <description>Blood was collected from RA participants prior to vaccination and at the Days 7 and 180 follow up visits for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
        <time_frame>Day 0 prior to and Days 7 and 180 following immunization</time_frame>
        <population>The analysis population includes all RA subjects enrolled and vaccinated with the 2011-2012 vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Days 7 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
          <description>Blood was collected from RA participants prior to vaccination and at the Days 7 and 180 follow up visits for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
          <population>The analysis population includes all RA subjects enrolled and vaccinated with the 2011-2012 vaccines.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Brisbane/60/2008 strain at Day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Brisbane/60/2008 strain at Day 180.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Perth/16/2009 (A/H3N2) strain at Day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Perth/16/2009 (A/H3N2) strain at Day 180.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 180.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Days 7 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
        <description>Blood was collected from RA participants prior to vaccination and at the Days 7 and 180 follow up visits for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
        <time_frame>Day 0 prior to and Days 7 and 180 following immunization</time_frame>
        <population>The analysis population includes RA participants enrolled and vaccinated with the 2012-2013 vaccines who had blood collected at the visit. One RA Participant, Standard Dose recipient is not included at Day 180 because the participant was out of window.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Days 7 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
          <description>Blood was collected from RA participants prior to vaccination and at the Days 7 and 180 follow up visits for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
          <population>The analysis population includes RA participants enrolled and vaccinated with the 2012-2013 vaccines who had blood collected at the visit. One RA Participant, Standard Dose recipient is not included at Day 180 because the participant was out of window.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Wisconsin/1/2010 - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Wisconsin/1/2010 - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Wisconsin/1/2010 strain at Day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.716</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Wisconsin/1/2010 strain at Day 180.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Victoria/361/2011 (A/H3N2) strain at Day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Victoria/361/2011 (A/H3N2) strain at Day 180.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.475</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 180.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of RA Participants With a Worsening Rheumatoid Arthritis Status During the Course of the Study, Based on the RAPID3 Score From the NP2 Questionnaire</title>
        <description>The RAPID 3 score is an index of the three patient-reported measures from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ) R808 and serves as an assessment of patient status for those with rheumatoid arthritis. The score consists of the cumulative total of the Function (FN), Pain (PN), and Patient Global (PTGL) values. The severity of the RAPID 3 score is categorized as: &gt;12=High Severity; 6.1-12=Moderate Severity; 3.1-6=Low Severity; and ≤3=Remission. The NP2 questionnaire was completed by RA participants at all clinic visits. Scores at Days 7, 21 and 180 were compared to Day 0 to determine worsening, defined as moving from the baseline category to a more severe category.</description>
        <time_frame>Day 0 to Days 7, 21 and 180</time_frame>
        <population>All RA participants are included in the analysis population for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O4">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants With a Worsening Rheumatoid Arthritis Status During the Course of the Study, Based on the RAPID3 Score From the NP2 Questionnaire</title>
          <description>The RAPID 3 score is an index of the three patient-reported measures from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ) R808 and serves as an assessment of patient status for those with rheumatoid arthritis. The score consists of the cumulative total of the Function (FN), Pain (PN), and Patient Global (PTGL) values. The severity of the RAPID 3 score is categorized as: &gt;12=High Severity; 6.1-12=Moderate Severity; 3.1-6=Low Severity; and ≤3=Remission. The NP2 questionnaire was completed by RA participants at all clinic visits. Scores at Days 7, 21 and 180 were compared to Day 0 to determine worsening, defined as moving from the baseline category to a more severe category.</description>
          <population>All RA participants are included in the analysis population for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in the 2011-2012 Season Who Achieved Seroconversion at Days 7, 21 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
        <description>Blood was collected from all participants prior to vaccination and at the Days 7, 21 and 180 follow up visits for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
        <time_frame>Day 0 prior to and Days 7, 21 and 180 following immunization</time_frame>
        <population>The analysis population includes all subjects enrolled and vaccinated with the 2011-2012 vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2011-2012 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in the 2011-2012 Season Who Achieved Seroconversion at Days 7, 21 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
          <description>Blood was collected from all participants prior to vaccination and at the Days 7, 21 and 180 follow up visits for testing in the HAI assay with 2011-2012 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
          <population>The analysis population includes all subjects enrolled and vaccinated with the 2011-2012 vaccines.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Perth/16/2009 (A/H3N2) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Brisbane/60/2008 strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Perth/16/2009 (A/H3N2) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.564</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Brisbane/60/2008 strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.564</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Perth/16/2009 (A/H3N2) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in the 2012-2013 Season Who Achieved Seroconversion at Days 7, 21 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
        <description>Blood was collected from all participants prior to vaccination and at the Days 7, 21 and 180 follow up visits for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
        <time_frame>Day 0 prior to and Days 7, 21 and 180 following immunization</time_frame>
        <population>The analysis population includes all subjects enrolled and vaccinated with the 2012-2013 vaccines who had blood collected at the visit. One RA Participant, Standard Dose and one Healthy Control, High Dose recipient are not included at Day 180 because the participant was out of window and lost to follow-up, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
            <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
          </group>
          <group group_id="O3">
            <title>RA Participants, 2012-2013 Fluzone High Dose</title>
            <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
          <group group_id="O4">
            <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
            <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in the 2012-2013 Season Who Achieved Seroconversion at Days 7, 21 and 180 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received</title>
          <description>Blood was collected from all participants prior to vaccination and at the Days 7, 21 and 180 follow up visits for testing in the HAI assay with 2012-2013 seasonal influenza vaccine strains virus as the assay antigens. A participant met the threshold of seroconversion if the Day 0 titer was less than 1:10 (the assay's lowest level of detection) and the Day 21 titer was 1:40 or greater, or the Day 0 titer was greater than or equal to 1:10 and the Day 21 titer was an increase by 4-fold or more.</description>
          <population>The analysis population includes all subjects enrolled and vaccinated with the 2012-2013 vaccines who had blood collected at the visit. One RA Participant, Standard Dose and one Healthy Control, High Dose recipient are not included at Day 180 because the participant was out of window and lost to follow-up, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Wisconsin/1/2010 - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Wisconsin/1/2010 - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Wisconsin/1/2010 - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/361/2011 (A/H3N2) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California/7/2009 (A/H1N1) - Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Wisconsin/1/2010 strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.180</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Victoria/361/2011 (A/H3N2) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.763</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the B/Wisconsin/1/2010 strain at Day 21</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/Victoria/361/2011 (A/H3N2) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.705</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is the comparison for the A/California/7/2009 (A/H1N1) strain at Day 21.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.132</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited events were collected for 8 days after vaccination, unsolicited non-serious adverse events through 21 days after vaccination, and serious adverse events and new onset chronic medical conditions through 180 days after vaccination.</time_frame>
      <desc>For events solicited on a Memory Aid in the 8 days after vaccination, a participant was considered to have one event if it was reported as experienced at any time in the 8 day period.</desc>
      <group_list>
        <group group_id="E1">
          <title>RA Participants, 2011-2012 Fluzone Standard Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls, 2011-2012 Fluzone Standard Dose</title>
          <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="E3">
          <title>RA Participants, 2011-2012 Fluzone High Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="E4">
          <title>Healthy Controls, 2011-2012 Fluzone High Dose</title>
          <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2011-2012 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="E5">
          <title>RA Participants, 2012-2013 Fluzone Standard Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="E6">
          <title>Healthy Controls, 2012-2013 Fluzone Standard Dose</title>
          <description>Healthy gender and age-matched controls were given a single 15 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone®</description>
        </group>
        <group group_id="E7">
          <title>RA Participants, 2012-2013 Fluzone High Dose</title>
          <description>Adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
        <group group_id="E8">
          <title>Healthy Controls, 2012-2013 Fluzone High Dose</title>
          <description>Healthy gender and age-matched controls were given a single 60 mcg intramuscular dose of 2012-2013 Sanofi Pasteur Fluzone® High Dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Solicited as &quot;feverishness&quot; on the memory aid</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" events="13" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Solicited as &quot;chills&quot; on the memory aid</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Solicited as &quot;shivering&quot; on the memory aid</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E8" events="10" subjects_affected="10" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" events="13" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="18" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="14" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jack Stapleton, MD</name_or_title>
      <organization>Department of Internal Medicine, University of Iowa</organization>
      <phone>319-356-3168</phone>
      <email>jack-stapleton@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

